C.R. Bard Inc. (New Jersey) (BCR)

331.24
1.95 0.59
NYSE : Health Technology
Prev Close 333.19
Open 333.49
Day Low/High 331.24 / 334.03
52 Wk Low/High 223.02 / 337.73
Volume 4.71M
Avg Volume 610.90K
Exchange NYSE
Shares Outstanding 72.89M
Market Cap 24.14B
EPS 7.20
P/E Ratio 43.70
Div & Yield 1.00 (0.00%)

Latest News

Cramer: Sorry, Popeye, but Market Rally Isn't Just About the French Connection

Cramer: Sorry, Popeye, but Market Rally Isn't Just About the French Connection

Let's play out what's allowing our markets to fly: Earnings.

Boston Scientific's Latest Quant Upgrade Reaffirms a Breakout Ahead

Boston Scientific's Latest Quant Upgrade Reaffirms a Breakout Ahead

A bullish market and another quant upgrade could push BSX past our $31 target.

Jim Cramer on Becton Dickinson's Purchase of Bard

Jim Cramer on Becton Dickinson's Purchase of Bard

TheStreet's Jim Cramer weighs in on Becton Dickinson's BDX purchase of Bard BCR for $24 billion.

Becton Dickinson Announces $24 Billion Acquisition of C.R. Bard

Becton Dickinson Announces $24 Billion Acquisition of C.R. Bard

Bard was shopped to BD as an acquisition target about 15 years ago

Wake Up Wall Street: Centrist Emmanuel Macron in the Driver's Seat to Enter the Elysee Palace

Wake Up Wall Street: Centrist Emmanuel Macron in the Driver's Seat to Enter the Elysee Palace

Here are five things you must know for Monday, April 24.

Cramer: Are You Paying Attention to These Boring Companies? You Should

Cramer: Are You Paying Attention to These Boring Companies? You Should

We ought to open our eyes to what we don't care about, to what's still made here.

C.R. Bard Just Keeps Going and Going...

C.R. Bard Just Keeps Going and Going...

Charts support further gains in the share price.

Cramer: The Best Performers Show No Signs of Letting Up

Cramer: The Best Performers Show No Signs of Letting Up

Their overseas business has been carrying them.

Cramer: We Have Nothing to Distinguish the Stocks Right Now

Cramer: We Have Nothing to Distinguish the Stocks Right Now

We know that we are in the era when index managers are ascendant.

Cramer: Top 10 Bull Markets Right Now

Cramer: Top 10 Bull Markets Right Now

Bull market number one, perhaps of all time: the financials.

Go With the Upside on C.R. Bard

Go With the Upside on C.R. Bard

Stock has bullish short-term and long-term charts.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

CR Bard upgraded at BMO

CR Bard upgraded at BMO

4 Market Segments to Avoid

4 Market Segments to Avoid

These sectors are full of high-priced, low-growth stocks.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Cramer: These Stocks Are the Key to the Bull Market

Cramer: These Stocks Are the Key to the Bull Market

Let me give you the unassailable themes.

Cramer: Don't Fall Prey to the Big Bears; Just Look at the Stocks

Cramer: Don't Fall Prey to the Big Bears; Just Look at the Stocks

There is so much buying power in so many new areas.

C.R. Baird Reverses Bullish Trajectory, Should Continue to Rally

C.R. Baird Reverses Bullish Trajectory, Should Continue to Rally

Traders should look to go long BCR near $210 if it pulls back.

C.R. Bard Does Not Look Very Healthy

C.R. Bard Does Not Look Very Healthy

Buyers should stay on the sidelines of Bard until a base is formed, potentially at a lower level.

Health Care Stocks Are Getting 'Uber-ed' by Ashton Kutcher

Health Care Stocks Are Getting 'Uber-ed' by Ashton Kutcher

Two significant, but subtle forces may threaten the group in the next 12 months.

CR Bard Is Heading for a Spill

CR Bard Is Heading for a Spill

We would begin trimming our position with a stop-loss just below $180.

Take a Hard Look at C.R. Bard; Shares Could Climb 15%

Take a Hard Look at C.R. Bard; Shares Could Climb 15%

With no top in sight, we remain bulls on this name.

Jim Cramer Says Buy Celgene at $113 or Below, Skyworks in the $70s

Jim Cramer Says Buy Celgene at $113 or Below, Skyworks in the $70s

Jim Cramer answered viewers' Twitter from the floor of the New York Stock Exchange, commenting on Qorvo (QRVO), Celgene (CELG), and Boston Scientific (BSX).

The Selling and the Damage Done

The Selling and the Damage Done

The last two days have changed the entire structure of the markets.

Stocks With Significant High Activity: the First Four Groups

Stocks With Significant High Activity: the First Four Groups

There are some good buying ideas among these stocks.

CR Bard upgraded at BofA/Merrill